ClinicalTrials.gg
CompletedNCT04640077Updated Jun 13, 2025Results posted

A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)

A Phase 2 interventional study of No Intervention and donanemab in Alzheimer Disease, Dementia and Brain Diseases, sponsored by Eli Lilly and Company. Completed at 27 sites in 2 countries. Open to participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-06-13.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
95
Allocation
Non-randomized
Ages
60 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing donanemab in Alzheimer Disease — 7 open to participants now, 10 under way, 6 of them phase 3. donanemab · Alzheimer Disease.

Enrollment
11th of 15
95 · median 240
Started
2020
with 1 other
Phase 2
4 of 15
2 open now
Registered
5th of 15
by date
Lead sponsor
12 of 15
Eli Lilly and Company

Among the 15 studies testing donanemab in Alzheimer Disease, this one is the 11th largest by enrollment, is one of 2 that started in 2020, is one of 4 in phase 2, and was the 5th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

7 of the 15 studies testing donanemab in Alzheimer Disease are open now, in 8 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About donanemab

donanemab: first FDA approval 2024 (KISUNLA), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 60 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing donanemab in Alzheimer Disease, or all of them as a file.
02

Study summary

The main goals of this study are to further determine whether the study drug donanemab is safe and effective in participants with Alzheimer's disease and to validate neuropsychological assessments administered over videoconferencing

03

Conditions studied

  • Alzheimer Disease
  • Dementia
  • Brain Diseases
  • Central Nervous System Diseases
  • Cognitive Impairment
04

Who can participate

Ages eligible
60 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participated in a double-blind treatment period of a sponsor-approved originating donanemab trial, for example the TRAILBLAZER-ALZ study.
  • Have a study partner
  • Stable symptomatic Alzheimer's Disease (AD) medications and other medication that may impact cognition for at least 30 days prior to randomization into Part A

Exclusion criteria

Exclusion Criteria:

  • Current serious or unstable illnesses including cardiovascular, hepatic, renal, gastroenterologic, respiratory, endocrinologic, neurologic (other than AD), psychiatric, immunologic, or hematologic disease and other conditions that, in the investigator's opinion, could interfere with outcome assessments or the analyses in this study.
  • Have received treatment with a passive anti-amyloid immunotherapy after completion of originating donanemab study or received active immunization against Aβ in any other study.
  • Poor venous access
  • to PET or MRI imaging
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
95 participants (actual)

Study arms

  • Other
    Part A: Validation of Remote Scale Assessments

    Participants from the originating trials did not receive any drug in Part A. Participants were randomized 1:1 into two groups to have their cognitive and functional scales assessed. Group 1: Cognitive/functional scale assessment at the study site (on-site), followed by an at-home assessment (VTC; video teleconference), or Group 2: Cognitive/functional scale assessment at home (VTC), followed by assessment on-site. Total time in Part A was up to 24 weeks.

    Other: No Intervention

  • Experimental
    Part B: Donanemab

    Participants who had received placebo in the originating trials received 700 milligrams (mg) donanemab administered intravenously (IV) every 4 weeks (Q4W) for 3 doses, then 1400 mg donanemab administered IV Q4W for up to 48 weeks.

    Drug: donanemab

Interventions

  • OtherNo Intervention

    No intervention

  • Administered IV

    Also known as: LY3002813

06

What researchers measure

Primary outcomes

  1. Part A: Intraclass Correlation Between On-Site and Video Teleconference (VTC) Assessments

    Part A didn't involve any drug and drug related efficacy analyses. Participants in Part A were divided into 2 groups, and they completed the same set of clinical assessments. Participants in Part A Group 1 completed the clinical assessments at a clinic site first (on-site) followed by at home assessments (VTC). Participants in Part A Group 2 completed the assessments at home first, followed by on-site assessment. The goal of Part A was to evaluate the comparability of remote and on-site clinical assessments. The intra-class correlation coefficient (ICC), a measure of agreement for continuous outcome measures, was used to determine agreement between remote and onsite assessments for each outcome measure. Outcome measure tested were the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog13), Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL), Mini Mental State Examination (MMSE), and Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB).

    Time frame: Baseline to 4 Weeks

  2. Part B: Percentage of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Percentage of participants with TEAEs and SAEs were reported here. A summary of SAEs and other non-serious AEs, regardless of causality is located in the Reported Adverse Events section of this record.

    Time frame: Baseline Up To 96 Weeks

  3. Part B: Number of Participants With Suicidality Based on Columbia-Suicide Severity Rating Scale (C-SSRS)

    Number of Participants with Suicidality Based on C-SSRS was reported.

    Time frame: Baseline, Week 72

Secondary outcomes

  1. Part B: Change From Baseline on the Mini Mental State Examination (MMSE) Score

    The MMSE is an instrument used to assess cognitive function in participants. The instrument measures orientation, memory, and attention; the ability of the participant to name objects; follow verbal and written commands; write a sentence; and copy figures. The range for the total MMSE score is 0 to 30, with lower scores indicating greater level of impairment. LS Mean was determined by Mixed Models for Repeated Measurements (MMRM) model with Baseline + Visit + Baseline\*Visit + Age + Years of Education + Presence/ Absence of Anti-dementia Drugs as variables.

    Time frame: Baseline, Week 72

  2. Part B: Change From Baseline on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) Score

    The ADAS-Cog13 (13-item version of ADAS Cog) assesses areas of cognitive function that are the most typically impaired in Alzheimer's Disease (AD): orientation, verbal memory, language, praxis, delayed free recall, digit cancellation, and maze-completion measures. The ADAS-Cog13 scale ranges from 0 to 85, with higher scores indicating greater disease severity. LS Mean was determined by MMRM model with Baseline + Visit + Baseline\*Visit + Age + Years of Education + Presence/Absence of Anti-dementia Drugs as variables.

    Time frame: Baseline, Week 72

  3. Part B: Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS)

    The iADRS is a composite that measures both cognition and function from the ADAS-Cog and the ADCS-iADL (Alzheimer's Disease Cooperative Study - instrumental Activities of Daily Living). The iADRS is calculated as a linear combination of the total scores of the ADAS-Cog13 (score range 0 to 85 with higher scores reflecting worse performance) and the ADCS-iADL (score range from 0-59 with higher scores reflecting better performance). The iADRS score ranges from 0 to 144 with lower scores indicating greater impairment. LS Mean was determined by MMRM model using Baseline + Visit + Baseline\*Visit + Age + Years of Education + Presence/Absence of Anti-dementia Drugs as variables.

    Time frame: Baseline, Week 72

  4. Part B: Change From Baseline on the Alzheimer's Disease Cooperative Study - Instrumental Activities of Daily Living (ADCS-iADL)

    The ADCS-iADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The range for the ADCS-iADL is 0-59 with higher scores reflecting better performance. LS Mean was determined by MMRM model using = Baseline + Visit + Baseline\*Visit + Age + Years of Education + Presence/Absence of Anti-dementia Drugs as variables.

    Time frame: Baseline, Week 72

  5. Part B: Change From Baseline on the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)

    The CDR-SB is a global assessment tool than can be used to effectively evaluate both cognition and function. Participant's cognitive status is rated across 6 domains or 'boxes' of functioning: Memory, Orientation, Judgment and Problem Solving, Community Affairs, Home and Hobbies, and Personal Care. The CDR-SB scores are calculated by adding the box scores and range from 0 to 18 with higher scores indicative of more impairment. LS Mean was determined by MMRM model using Baseline + Visit + Baseline\*Visit + Age + Years of Education + Presence/Absence of Anti-dementia Drugs as variables.

    Time frame: Baseline, Week 72

  6. Part B: Change From Baseline in Brain Amyloid Plaque Deposition as Measured by Florbetapir F18 Positron Emission Tomography (PET) Scan

    Florbetapir PET imaging was used as a quantitative amyloid biomarker. Florbetapir PET scans at baseline and at 36 weeks after the first treatment were used to quantitatively estimate change in amyloid plaques. Quantitative amyloid burden was first formalized as the average Standardized Uptake Value Ratio (SUVR) in six predetermined cortical areas of the brain relative to the cerebellum as a reference region. Larger SUVR reflects the larger cortical amyloid burden relative to cerebellum. SUVR values were further calibrated to a centiloid (CL) scale. The Centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan. LS Mean was determined by ANCOVA model using originating study's Baseline + Age + Treatment (Type III sum of squares) as variables.

    Time frame: Baseline, Week 36

  7. Part B: Change From Baseline in Whole Brain Volume as Measured by Volumetric Magnetic Resonance Imaging (vMRI)

    Change from Baseline in Whole Brain Volume as Measured by vMRI in Part B. LS mean were derived using MMRM model with fixed factors for visit, and covariates for baseline score, and age at baseline.

    Time frame: Baseline, Week 72

  8. Part B: Pharmacokinetics (PK): Trough Concentrations of Donanemab (Ctrough)

    PK: Trough Concentration of donanemab. Ctrough is the concentration of drug in the blood immediately before the next dose of drug was administered.

    Time frame: Predose at Week 8 and Week 16

  9. Part B: Number or Participants With Treatment-Emergent Anti-Drug Antibodies (TE ADA) of Donanemab

    Number of participants in Part B with positive Anti-drug antibodies (TE ADA+) was reported. A TE ADA evaluable participant is classified as TE ADA+ if they have at least one postbaseline titer that is 4 times or more higher than the baseline titer (treatment-boosted). If the baseline result is ADA Not Present, the subject is considered TE ADA+ if there is at least one postbaseline result showing ADA present with a titer of 1:10 or higher (treatment-induced).

    Time frame: Baseline, 4, 8, 16, 24, 36, 48, 60, 72, 84, and 96 Weeks

07

Results

Posted Jun 13, 2025

Participant flow

Study AACH was an extension of sponsor-approved originating donanemab studies AACC (NCT01837641) and AACG (NCT03367403). This was a two-part study (Parts A and B). Participants received the study drug only in Part B, whereas Part A consisted of clinical assessments.

Period 1
Participant flow — Period 1
MilestonePart A - Group 1: Validation of Remote Scale AssessmentsPart A - Group 2: Validation of Remote Scale AssessmentsPart B: Donanemab
Started50450
Received at least 1 dose of study drug000
Completed43390
Not completed760
Withdrew: Withdrawal by subject450
Withdrew: Adverse event110
Withdrew: Screen failure200
Period 2
Participant flow — Period 2
MilestonePart A - Group 1: Validation of Remote Scale AssessmentsPart A - Group 2: Validation of Remote Scale AssessmentsPart B: Donanemab
Started0055
Received at least 1 dose of study drug0055
Completed0025
Not completed0030
Withdrew: Withdrawal by subject0018
Withdrew: Adverse event006
Withdrew: Lost to follow-up002
Withdrew: Death002
Withdrew: Progressive disease001
Withdrew: Withdrawal due to caregiver circumstances001

Outcome measures

PrimaryPart A: Intraclass Correlation Between On-Site and Video Teleconference (VTC) Assessments

Part A didn't involve any drug and drug related efficacy analyses. Participants in Part A were divided into 2 groups, and they completed the same set of clinical assessments. Participants in Part A Group 1 completed the clinical assessments at a clinic site first (on-site) followed by at home assessments (VTC). Participants in Part A Group 2 completed the assessments at home first, followed by on-site assessment. The goal of Part A was to evaluate the comparability of remote and on-site clinical assessments. The intra-class correlation coefficient (ICC), a measure of agreement for continuous outcome measures, was used to determine agreement between remote and onsite assessments for each outcome measure. Outcome measure tested were the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog13), Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL), Mini Mental State Examination (MMSE), and Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB).

Time frame:
Baseline to 4 Weeks
Reported as:
Number · Intraclass correlation coefficient
Part A: Intraclass Correlation Between On-Site and Video Teleconference (VTC) Assessments
Intraclass correlation coefficientPart A: Validation of Remote Scale Assessments
ADAS-Cog130.8172 (0.7293 to 0.8785)
ADCS-ADL0.8819 (0.8227 to 0.9222)
MMSE0.8251 (0.7148 to 0.8907)
CDR-SB0.8254 (0.7380 to 0.8852)
PrimaryPart B: Percentage of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

Percentage of participants with TEAEs and SAEs were reported here. A summary of SAEs and other non-serious AEs, regardless of causality is located in the Reported Adverse Events section of this record.

Time frame:
Baseline Up To 96 Weeks
Reported as:
Number · Percentage of participants
Part B: Percentage of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Percentage of participantsPart B: Donanemab
TEAEs90.9
SAEs29.1
PrimaryPart B: Number of Participants With Suicidality Based on Columbia-Suicide Severity Rating Scale (C-SSRS)

Number of Participants with Suicidality Based on C-SSRS was reported.

Time frame:
Baseline, Week 72
Reported as:
Count of participants · Participants
Part B: Number of Participants With Suicidality Based on Columbia-Suicide Severity Rating Scale (C-SSRS)
ParticipantsPart B: Donanemab
Suicidal Ideation3
Suicidal Behavior1
SecondaryPart B: Change From Baseline on the Mini Mental State Examination (MMSE) Score

The MMSE is an instrument used to assess cognitive function in participants. The instrument measures orientation, memory, and attention; the ability of the participant to name objects; follow verbal and written commands; write a sentence; and copy figures. The range for the total MMSE score is 0 to 30, with lower scores indicating greater level of impairment. LS Mean was determined by Mixed Models for Repeated Measurements (MMRM) model with Baseline + Visit + Baseline\*Visit + Age + Years of Education + Presence/ Absence of Anti-dementia Drugs as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Score on a scale
Part B: Change From Baseline on the Mini Mental State Examination (MMSE) Score
Score on a scalePart B: Donanemab
Part B: Change From Baseline on the Mini Mental State Examination (MMSE) Score-0.87 ± 0.557
SecondaryPart B: Change From Baseline on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) Score

The ADAS-Cog13 (13-item version of ADAS Cog) assesses areas of cognitive function that are the most typically impaired in Alzheimer's Disease (AD): orientation, verbal memory, language, praxis, delayed free recall, digit cancellation, and maze-completion measures. The ADAS-Cog13 scale ranges from 0 to 85, with higher scores indicating greater disease severity. LS Mean was determined by MMRM model with Baseline + Visit + Baseline\*Visit + Age + Years of Education + Presence/Absence of Anti-dementia Drugs as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Score on a scale
Part B: Change From Baseline on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) Score
Score on a scalePart B: Donanemab
Part B: Change From Baseline on the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) Score4.63 ± 1.195
SecondaryPart B: Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS)

The iADRS is a composite that measures both cognition and function from the ADAS-Cog and the ADCS-iADL (Alzheimer's Disease Cooperative Study - instrumental Activities of Daily Living). The iADRS is calculated as a linear combination of the total scores of the ADAS-Cog13 (score range 0 to 85 with higher scores reflecting worse performance) and the ADCS-iADL (score range from 0-59 with higher scores reflecting better performance). The iADRS score ranges from 0 to 144 with lower scores indicating greater impairment. LS Mean was determined by MMRM model using Baseline + Visit + Baseline\*Visit + Age + Years of Education + Presence/Absence of Anti-dementia Drugs as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Score on a scale
Part B: Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS)
Score on a scalePart B: Donanemab
Part B: Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS)-10.14 ± 1.850
SecondaryPart B: Change From Baseline on the Alzheimer's Disease Cooperative Study - Instrumental Activities of Daily Living (ADCS-iADL)

The ADCS-iADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The range for the ADCS-iADL is 0-59 with higher scores reflecting better performance. LS Mean was determined by MMRM model using = Baseline + Visit + Baseline\*Visit + Age + Years of Education + Presence/Absence of Anti-dementia Drugs as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Score on a scale
Part B: Change From Baseline on the Alzheimer's Disease Cooperative Study - Instrumental Activities of Daily Living (ADCS-iADL)
Score on a scalePart B: Donanemab
Part B: Change From Baseline on the Alzheimer's Disease Cooperative Study - Instrumental Activities of Daily Living (ADCS-iADL)-6.21 ± 1.149
SecondaryPart B: Change From Baseline on the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)

The CDR-SB is a global assessment tool than can be used to effectively evaluate both cognition and function. Participant's cognitive status is rated across 6 domains or 'boxes' of functioning: Memory, Orientation, Judgment and Problem Solving, Community Affairs, Home and Hobbies, and Personal Care. The CDR-SB scores are calculated by adding the box scores and range from 0 to 18 with higher scores indicative of more impairment. LS Mean was determined by MMRM model using Baseline + Visit + Baseline\*Visit + Age + Years of Education + Presence/Absence of Anti-dementia Drugs as variables.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · Score on a scale
Part B: Change From Baseline on the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)
Score on a scalePart B: Donanemab
Part B: Change From Baseline on the Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB)1.87 ± 0.364
SecondaryPart B: Change From Baseline in Brain Amyloid Plaque Deposition as Measured by Florbetapir F18 Positron Emission Tomography (PET) Scan

Florbetapir PET imaging was used as a quantitative amyloid biomarker. Florbetapir PET scans at baseline and at 36 weeks after the first treatment were used to quantitatively estimate change in amyloid plaques. Quantitative amyloid burden was first formalized as the average Standardized Uptake Value Ratio (SUVR) in six predetermined cortical areas of the brain relative to the cerebellum as a reference region. Larger SUVR reflects the larger cortical amyloid burden relative to cerebellum. SUVR values were further calibrated to a centiloid (CL) scale. The Centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan. LS Mean was determined by ANCOVA model using originating study's Baseline + Age + Treatment (Type III sum of squares) as variables.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · Centiloids
Part B: Change From Baseline in Brain Amyloid Plaque Deposition as Measured by Florbetapir F18 Positron Emission Tomography (PET) Scan
CentiloidsPart B: Donanemab
Part B: Change From Baseline in Brain Amyloid Plaque Deposition as Measured by Florbetapir F18 Positron Emission Tomography (PET) Scan-80.1 ± 4.40
SecondaryPart B: Change From Baseline in Whole Brain Volume as Measured by Volumetric Magnetic Resonance Imaging (vMRI)

Change from Baseline in Whole Brain Volume as Measured by vMRI in Part B. LS mean were derived using MMRM model with fixed factors for visit, and covariates for baseline score, and age at baseline.

Time frame:
Baseline, Week 72
Reported as:
Least squares mean · cubic centimeters (cm3)
Part B: Change From Baseline in Whole Brain Volume as Measured by Volumetric Magnetic Resonance Imaging (vMRI)
cubic centimeters (cm3)Part B: Donanemab
Part B: Change From Baseline in Whole Brain Volume as Measured by Volumetric Magnetic Resonance Imaging (vMRI)-27.75 ± 2.060
SecondaryPart B: Pharmacokinetics (PK): Trough Concentrations of Donanemab (Ctrough)

PK: Trough Concentration of donanemab. Ctrough is the concentration of drug in the blood immediately before the next dose of drug was administered.

Time frame:
Predose at Week 8 and Week 16
Reported as:
Geometric mean · micrograms per milliliter (μg/mL)
Part B: Pharmacokinetics (PK): Trough Concentrations of Donanemab (Ctrough)
micrograms per milliliter (μg/mL)Part B: Donanemab
Ctrough at Week 85.62 ± 165
Ctrough at Week 166.64 ± 581
SecondaryPart B: Number or Participants With Treatment-Emergent Anti-Drug Antibodies (TE ADA) of Donanemab

Number of participants in Part B with positive Anti-drug antibodies (TE ADA+) was reported. A TE ADA evaluable participant is classified as TE ADA+ if they have at least one postbaseline titer that is 4 times or more higher than the baseline titer (treatment-boosted). If the baseline result is ADA Not Present, the subject is considered TE ADA+ if there is at least one postbaseline result showing ADA present with a titer of 1:10 or higher (treatment-induced).

Time frame:
Baseline, 4, 8, 16, 24, 36, 48, 60, 72, 84, and 96 Weeks
Reported as:
Count of participants · Participants
Part B: Number or Participants With Treatment-Emergent Anti-Drug Antibodies (TE ADA) of Donanemab
ParticipantsPart B: Donanemab
Part B: Number or Participants With Treatment-Emergent Anti-Drug Antibodies (TE ADA) of Donanemab38

Adverse events

Collected over Baseline Up To 96 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period 1: Part A - Group 1: Validation of Remote Scale Assessments0/50 (0%)0/50 (0%)0/50 (0%)
Period 1: Part A - Group 2: Validation of Remote Scale Assessments0/45 (0%)1/45 (2.2%)0/45 (0%)
Period 2: Part B: Donanemab2/55 (3.6%)16/55 (29.1%)40/55 (72.7%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventPeriod 1: Part A - Group 1: Validation of Remote Scale AssessmentsPeriod 1: Part A - Group 2: Validation of Remote Scale AssessmentsPeriod 2: Part B: Donanemab
Amyloid related imaging abnormality-oedema/effusionNervous system disorders0/500/453/55
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin depositsNervous system disorders0/500/452/55
SyncopeNervous system disorders0/501/451/55
Acute myocardial infarctionCardiac disorders0/500/451/55
Atrial fibrillationCardiac disorders0/500/451/55
Cardiac failure congestiveCardiac disorders0/500/451/55
Gastrointestinal haemorrhageGastrointestinal disorders0/500/451/55
FatigueGeneral disorders0/500/451/55
CellulitisInfections and infestations0/500/451/55
Covid-19Infections and infestations0/500/451/55
Most frequent other events
Showing 10 of 14
Most frequent other events
EventPeriod 1: Part A - Group 1: Validation of Remote Scale AssessmentsPeriod 1: Part A - Group 2: Validation of Remote Scale AssessmentsPeriod 2: Part B: Donanemab
Amyloid related imaging abnormality-oedema/effusionNervous system disorders0/500/4515/55
Amyloid related imaging abnormality-microhaemorrhages and haemosiderin depositsNervous system disorders0/500/4510/55
Infusion related reactionInjury, poisoning and procedural complications0/500/458/55
Covid-19Infections and infestations0/500/457/55
FallInjury, poisoning and procedural complications0/500/457/55
Urinary tract infectionInfections and infestations0/500/456/55
HeadacheNervous system disorders0/500/454/55
AstheniaGeneral disorders0/500/453/55
Blood pressure increasedInvestigations0/500/453/55
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/500/453/55

Baseline characteristics

All enrolled participants in Part A.

Age, Continuous
Age, Continuous(years)Part A: Validation of Remote Scale Assessments
Mean77.8 ± 5.6
Sex: Female, Male
Sex: Female, Male(Participants)Part A: Validation of Remote Scale Assessments
Female52
Male43
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: Validation of Remote Scale Assessments
Hispanic or Latino3
Not Hispanic or Latino83
Unknown or Not Reported9
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part A: Validation of Remote Scale Assessments
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White93
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Part A: Validation of Remote Scale Assessments
Canada9
United States86
08

Study locations

27 sites
  • Banner Alzheimer's Institute
    Phoenix, Arizona 85006, United States
  • UC Irvine-Institute for Memory Impairments and Neurological Disorders (UCI MIND)
    Irvine, California 92697, United States
  • Bradenton Research Center, Inc.
    Bradenton, Florida 34205, United States
  • Merritt Island Medical Research, LLC
    Merritt Island, Florida 32952, United States
  • Synexus Clinical Research US, Inc.
    Orlando, Florida 32806, United States
  • Advanced Research Consultants
    Palm Beach Gardens, Florida 33410, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Intercoastal Medical Group - Hyde Park
    Sarasota, Florida 34239, United States
  • Stedman Clinical Trials
    Tampa, Florida 33613, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • Josephson Wallack Munshower Neurology, PC
    Indianapolis, Indiana 46256, United States
  • The University of Kansas - Clinical Research Center
    Fairway, Kansas 66205, United States
  • Cotton O'Neil Clinical Research Center - Central Office
    Topeka, Kansas 66606, United States
  • Boston Center for Memory
    Newton, Massachusetts 02459, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • Las Vegas Medical Research
    Las Vegas, Nevada 89113, United States
  • Advanced Memory Research Institute of New Jersey
    Toms River, New Jersey 08755, United States
  • Guilford Neurologic Research, PA
    Greensboro, North Carolina 27405, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Neurology Diagnostics, Inc.
    Dayton, Ohio 45459, United States
  • Abington Neurological Associates, Ltd.
    Abington, Pennsylvania 19001, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • National Clinical Research, Inc
    Richmond, Virginia 23294, United States
  • Bruyère Research Institute
    Ottawa, Ontario K1N 5C8, Canada
  • Toronto Memory Program
    Toronto, Ontario M3B 2S7, Canada
  • Clinique de la Mémoire de l'Outaouais
    Gatineau, Quebec J8T 8J1, Canada
  • Diex Recherche Sherbrooke Inc.
    Sherbrooke, Quebec J1L 0H8, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: Access Criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Feb 2024, 39 months.

Results were first posted in Jun 2025, 1 year 3 months after primary completion.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 39 months is above that.

Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2020
First posted
Nov 23, 2020
StartActual
Nov 23, 2020
Primary completionActual
Feb 27, 2024
CompletionActual
Feb 27, 2024
Results first posted
Jun 13, 2025
Last update
Jun 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04640077
Responsible party
Sponsor
First posted
Nov 23, 2020
Start date
Nov 23, 2020
Primary completion
Feb 27, 2024
Completion
Feb 27, 2024
Results posted
Jun 13, 2025
Last update
Jun 13, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donanemab

Start the discussion